Divi's Laboratories
DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com

Stock Price vs Company Growth
1d
2.1%
1w
3.0%
1m
2.2%
3m
7.8%
6m
4.4%
1y
57.3%
5y
25.4%
10y
21.2%
all
22.9%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

5,663 2.1%
5,355
6,227
Company Overview

Sales
9,078 Cr
Growth: 11.4%
Profit after Tax
2,067 Cr
Growth: 12.6%
Large Cap
1,50,343 Cr
P/E: 72.7x
Industry P/E: 32.5x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 9,078
Growth 11.4%
EBITDA 31.0%
P/S 16.6x
Dividend 0.6%
P/E 72.7x
Book Value ₹ 569
PEG Ratio 6.4x
ROE 14.5%
P/B 10.0x
Shareholding Pattern

Institutions
Sbi Mutual Fund
4.49 %
Qualified Institutional Buyer
3.57 %
Axis Mutual Fund Trustee Ltd
3.37 %
Government Pension Fund Global
1.29 %
Life Insurance Corporation Of India
1.15 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar22Sep22Mar24Sep24
Promoters
Nilima Prasad Divi
20.34 %
Divi Satchandra Kiran
20.34 %
Divi Swarna Latha
5.27 %
Divi'S Biotech Private Limited
3.01 %
Murali Krishna Prasad Divi
2.85 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar22Sep22Mar24Sep24
Others
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar22Sep22Mar24Sep24
Increase    Decrease    No change
Company Profile Detailed

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.
Investors (131)
Followers (42)